Treatment Approach to ROS1 Rearranged NSCLC

480 views
October 19, 2023
On November 15, 2023, the FDA approved repotrectinib (brand name Augtyro) for locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Comments 0
Login to view comments. Click here to Login